Tyr367

Site Information
CFEYQKLytyIQsRF SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 461929

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:	bile-duct cancer ( 1 ) , lung cancer ( 2 , 3 ) , non-small cell lung cancer ( 3 ) , non-small cell squamous cell lung carcinoma ( 2 )
Relevant cell line - cell type - tissue:	EGI-1 (bile-duct cell) ( 1 ) , lung ( 2 ) , NCI-H1993 (pulmonary) ( 3 )

References
1	Tucker M (2008) CST Curation Set: 5479; Year: 2008; Biosample/Treatment: cell line, EGI-1/untreated; Disease: bile-duct cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
2	Ren H (2008) CST Curation Set: 5493; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
3	Rikova K (2005) CST Curation Set: 612; Year: 2005; Biosample/Treatment: cell line, NCI-H1993/serum starved &'\|\|' NULL; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info